Intravitreal ranibizumab and bevacizumab in combination with full-fluence verteporfin therapy and dexamethasone for exudative age-related macular degeneration.

Abstract PURPOSE: To evaluate the efficacy and safety of triple therapy with intravitreal anti-vascular-endothelial-growth-factor (VEGF) antibody, dexamethasone and verteporfin photodynamic therapy (PDT) for exudative age-related macular degeneration (AMD). METHODS: Retrospective, comparative, interventional study. Records of treatment-naïve patients who received intravitreal bevacizumab or ranibizumab in monotherapy or in combination with dexamethasone and full-fluence verteporfin PDT in triple therapy were reviewed. logMAR visual acuity, foveal thickness (FT) on optical coherence tomography, intraocular pressure and endophthalmitis occurrence were recorded. RESULTS: Sixty-one eyes were included in the triple-therapy group, 40 eyes were included in the monotherapy group. The mean follow-up was 14.1 ± 3.4 months in the triple-therapy group and 16.3 ± 4.1 months in the monotherapy group. The triple-therapy group enjoyed a lower total number of treatments (1.92 ± 0.44 vs. 3.12 ± 0.37, p < 0.001) and a longer time before first retreatment (5.4 ± 3.3 vs. 3.6 ± 2.5 months, p = 0.001). A significant improvement of visual acuity and FT was present in both groups during the 12 months following first treatment. No adverse effects were observed. CONCLUSION: The combination of intravitreal bevacizumab or ranibizumabwith dexamethasone and full-fluence PDT for exudative AMD provided visual and anatomic improvement and a good safety profile. Triple therapy may reduce the number of retreatments when compared to anti-VEGF alone

A versatile electrolyte system for electrodeposition of p-block elements from single ohase supercritical CH2F2

For the first time, a versatile electrolyte bath is described that can be used to electrodeposit a wide range of p-block elements from supercritical difluoromethane (scCH2F2). The bath comprises the tetrabutylammonium chlorometallate complex of the element in an electrolyte of 50×10−3 mol dm−3 tetrabutylammonium chloride at 17.2 MPa and 358 K. Through the use of anionic ([GaCl4]−, [InCl4]−, [GeCl3]−, [SnCl3]−, [SbCl4]−, and [BiCl4]−) and dianionic ([SeCl6]2− and [TeCl6]2−) chlorometallate salts, the deposition of elemental Ga, In, Ge, Sn, Sb, Bi, Se, and Te is demonstrated. In all cases, with the exception of gallium, which is a liquid under the deposition conditions, the resulting deposits are characterised by SEM, energy-dispersive X-ray analysis, XRD and Raman spectroscopy. An advantage of this electrolyte system is that the reagents are all crystalline solids, reasonably easy to handle and not highly water or oxygen sensitive. The results presented herein significantly broaden the range of materials accessible by electrodeposition from supercritical fluid and open up the future possibility of utilising the full scope of these unique fluids to electrodeposit functional binary or ternary alloys and compounds of these elements

Preoperative chemoradiation with paclitaxel-carboplatin or with fluorouracil-oxaliplatin-folinic acid (FOLFOX) for resectable esophageal and junctional cancer: the PROTECT-1402, randomized phase 2 trial.

BACKGROUND: Often curative treatment for locally advanced resectable esophageal or gastro-esophageal junctional cancer consists of concurrent neoadjuvant radiotherapy and chemotherapy followed by surgery. Currently, one of the most commonly used chemotherapy regimens in this setting is a combination of a fluoropyrimidin and of a platinum analogue. Due to the promising results of the recent CROSS trial, another regimen combining paclitaxel and carboplatin is also widely used by European and American centers. No clinical study has shown the superiority of one treatment over the other. The objective of this Phase II study is to clarify clinical practice by comparing these two chemotherapy treatments. Our aim is to evaluate, in operable esophageal and gastro-esophageal junctional cancer, the complete resection rate and severe postoperative morbidity rate associated with these two neoadjuvant chemotherapeutic regimens (carboplatin-paclitaxel or fluorouracil-oxaliplatin-folinic acid) when each is combined with the radiation regime utilized in the CROSS trial. METHODS/DESIGN: PROTECT is a prospective, randomized, multicenter, open arms, phase II trial. Eligible patients will have a histologically confirmed adenocarcinoma or squamous cell carcinoma and be treated with neoadjuvant radiochemotherapy followed by surgery for stage IIB or stage III resectable esophageal cancer. A total of 106 patients will be randomized to receive either 3 cycles of FOLFOX combined to concurrent radiotherapy (41.4 Grays) or carboplatin and paclitaxel with the same radiation regimen, using a 1:1 allocation ratio. DISCUSSION: This ongoing trial offers the unique opportunity to compare two standards of chemotherapy delivered with a common regimen of preoperative radiation, in the setting of operable locally advanced esophageal or gastro-esophageal junctional tumors. TRIAL REGISTRATION: NCT02359968 (ClinicalTrials.gov) (registration date: 9 FEB 2015), EudraCT: 2014-000649-62 (registration date: 10 FEB 2014)

PELAKSANAAN PENDAFTARAN PRODUK KOSMETIK POMADE DI KOTA PEKANBARU MENURUT PERATURAN KBPOM NO. HK.03.1.23.12.11.10052 TAHUN 2011 TENTANG PENGAWASAN DAN PEREDARAN KOSMETIKA

ABSTRAK Berdasarkan Peraturan KBPOM No.HK.03.1.23.12.11.10052 tentang Pengawasan dan Peredaran Kosmetika Pasal 2 yang menyatakan bahwa “Setiap kosmetika yang beredar wajib memenuhi standar dan/ atau persyaratan keamanan, manfaat, mutu, penandaan, klaim, dan dinotifikasi”. Namun pada kenyataannya per tanggal 10 Desember 2019 produk kosmetika Pomade yang ternotifikasi pada BPOM sebanyak 505 produk kosmetika Pomade dan masih banyak produk kosmetika pomade lainnya yang belum ternotifikasi pada BPOM. Berdasarkan hal tersebut, maka penulis merumuskan bagaimanakah tinjuan hukum mengenai kosmetik Pomade yang tidak ternotifikasi dari BPOM Pekanbaru dan bagaimana akibat hukum bagi produk-produk kosmetik Pomade yang belum terdaftar BPOM namun telah dipasarkan. Jenis penelitian ini tergolong kepada Yuridis Sosiologis, sedangkan sifat penelitian ini adalah penelitian deskriptif. Maksud dari deskriptif adalah penilaian yang memberikan gambaran secara jelas dan terperinci mengenai pengawasan dan peredaran produk kosmetika Pomade ditinjau berdasarkan Peraturan KBPOM No.HK.03.1.23.12.11.10052 tentang Pengawasan dan Peredaran Kosmetika. Dari hasil penelitian menunjukkan bahwa tinjaun hukum mengenai produk kosmetik Pomade yang tidak terdaftar di BPOM belum efektif karena masih banyaknya produk kosmetik termasuk kosmetik Pomade masih beredar tanpa mendaftarkan produknya ke BPOM. Akibat hukum produk Kosmetik yang tidak terdaftar yaitu sanksi administrasi berupa peringatan tertulis dan larangan pengedarkan kosmetik.Jika sanksi pidana yang dijatuhkan kepada pelaku yang tidak betanggung jawab, sanksi pidana tersebut bergantung terhadap undang- undang yang dilanggar oleh pelaku. Kata Kunci: Brand Image dan Keputusan Pembelia

Regulación de la expresión y función del receptor GPR55 en la homeostasis energética y metabólica

Existen mecanismos, moleculares, celulares y comportamentales implicados en la regulación de la ingesta de alimentos, el gasto de energía y la obesidad. En este sentido, la obesidad, se ha definido como el resultado de un almacenamiento de calorías que excede los requerimientos de energía del organismo, y en consecuencia, la interacción entre factores genéticos, medioambientales que la promueven y el sistema de control homeostático, contribuyen al desarrollo de diferentes tipos de obesidad, convirtiéndola en la enfermedad del siglo XXI (Morton et al., 2006). En el presente trabajo abordamos las funciones metabólicas desempeñadas por el sistema LPI/GPR55, dado que el receptor GPR55 es un receptor putativo cannabinoide y se sabe que el sistema endocannabinoide está involucrado en la regulación de la homeostasis energética (Rodriguez de Fonseca F. et al., 2005) (Di Marzo, 2006; Fowler et al., 2005; Ross, 2009)

Frequency of Certain Established Risk Factors in Soft Tissue Sarcomas in Adults: A Prospective Descriptive Study of 658 Cases

Soft tissue sarcomas are rare tumours with infrequent identified aetiological factors. Several genetic syndromes as well as previous radiation therapy and/or chronic lymphoedema have been suspected to predispose to some soft tissue sarcomas. Between January 1997 and September 2005, we carried out a prospective descriptive study to estimate the frequency of some particular etiological factors among 658 patients with soft tissue sarcomas. Sarcomas associated with a clinically identified genetic disease represent 2.8% out of all cases (95%CI: 1.5–3.8%). Most of these cases (14/19) are related to Recklinghausen neurofibromatosis. Radiation-induced sarcomas represent 3.3% out of all cases (95%CI: 1.7–5.1%). Most of these cases (9/22) are related to prior breast cancer treatment. We had observed only 1 case of Stewart-Treves syndrome. Liposarcoma, the most frequent histological subtype observed, is not associated with any particular aetiological entity. Finally, most of the adult soft tissue sarcomas are not related to any classical clinically identified genetic disease or previous radiation therapy and/or chronic lymphoedema risk factors. Frequency of underlying genetic syndrome which may predispose to soft tissue sarcomas could be higher than previously reported

Infecção por VIH entre imigrantes na Guiana Francesa: alto risco durante os primeiros anos após a chegada

Introduction. Over 75% of HIV patients in French Guiana are foreigners most of whom are actually infected locally.&nbsp;Objectives. We aimed to estimate the distribution of infections in time after arrival using a retrospective cohort.&nbsp;Methods. CD4 erosion modelling allowed to estimate the date of infection which was compared to the date of arrival in French Guiana in the subset of foreign patients that were estimated to have acquired HIV locally.&nbsp;Results. Among patients estimated to have been infected in French Guiana and having arrived after 1999, over half had been infected within 4 years and that a quarter of patients had acquired HIV within the 2 first years after arrival (median 3.9 years IQR=2.1-7.8 years).&nbsp;Conclusions. The added value of the present results is to show the rapid infection dynamics after arrival and emphasize the necessity of increasingly proactive combined prevention in recently arrived immigrants.Introdução. Mais de 75% dos pacientes com HIV na Guiana Francesa são estrangeiros, a maioria dos quais estão realmente infectados localmente.&nbsp;Objetivos. O nosso objetivo era estimar a distribuição das infecções no tempo após a chegada, utilizando uma coorte retrospectiva.&nbsp;Métodos. A modelagem da erosão CD4 permitiu estimar a data da infecção que foi comparada à data de chegada na Guiana Francesa no subconjunto de pacientes estrangeiros que foram estimados como tendo adquirido o HIV localmente.Resultados. Entre os pacientes estimados como tendo sido infectados na Guiana Francesa e tendo chegado após 1999, mais da metade tinha sido infectada dentro de 4 anos e que um quarto dos pacientes tinha adquirido o HIV dentro dos 2 primeiros anos após a chegada (mediana de 3,9 anos IQR=2,1-7,8 anos). Conclusões. O valor agregado dos resultados atuais é mostrar a rápida dinâmica da infecção após a chegada e enfatizar a necessidade de uma prevenção combinada cada vez mais proativa nos imigrantes recém-chegados

Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus

A locus at 19p13 is associated with breast cancer (BC) and ovarian cancer (OC) risk. Here we analyse 438 SNPs in this region in 46,451 BC and 15,438 OC cases, 15,252 BRCA1 mutation carriers and 73,444 controls and identify 13 candidate causal SNPs associated with serous OC (P=9.2 × 10-20), ER-negative BC (P=1.1 × 10-13), BRCA1-associated BC (P=7.7 × 10-16) and triple negative BC (P-diff=2 × 10-5). Genotype-gene expression associations are identified for candidate target genes ANKLE1 (P=2 × 10-3) and ABHD8 (P<2 × 10-3). Chromosome conformation capture identifies interactions between four candidate SNPs and ABHD8, and luciferase assays indicate six risk alleles increased transactivation of the ADHD8 promoter. Targeted deletion of a region containing risk SNP rs56069439 in a putative enhancer induces ANKLE1 downregulation; and mRNA stability assays indicate functional effects for an ANKLE1 3′-UTR SNP. Altogether, these data suggest that multiple SNPs at 19p13 regulate ABHD8 and perhaps ANKLE1 expression, and indicate common mechanisms underlying breast and ovarian cancer risk